Indaptus Therapeutics filings document a clinical-stage biotechnology issuer developing Decoy20 and related immunotherapy programs for cancer and viral infections. The company’s regulatory record includes material-event reports, proxy statements, capital-structure disclosures, and governance filings tied to its Nasdaq-listed common stock.
Key filing subjects include convertible preferred stock, warrants, warrant repricing agreements, voting agreements, unregistered securities, shareholder meeting proposals, and changes in control. The filings also cover board and officer appointments or resignations, compensatory arrangements, operating and financial results, and material agreements that affect the company’s financing, governance, and public-company structure.
Indaptus Therapeutics CEO Junyi Dai reports his current ownership stake in the company’s common stock. He beneficially owns 11,250,000 shares, representing 8.44% of Indaptus Therapeutics’ common stock, based on 133,242,324 shares outstanding as of June 24, 2026.
Dai acquired these shares through a Securities Purchase Agreement dated March 19, 2026, using personal funds of $1,156,642.43 to buy Series AA and Series AAA Preferred Stock that later converted into common shares. The filing notes that his percentage ownership fell by more than 1% solely because the company issued additional shares in a private placement on June 17, 2026; he did not buy or sell any common shares in connection with that event.
Indaptus Therapeutics investor Ting Yang has updated his ownership report. He beneficially owns 11,250,000 shares of Indaptus Therapeutics, Inc. common stock, representing 8.44% of the outstanding shares as of June 24, 2026. The stake comes from Series AA and Series AAA Preferred Stock converted under a Securities Purchase Agreement dated March 19, 2026, which closed on March 23, 2026.
This amendment reports that Yang’s percentage ownership fell by more than 1% because Indaptus completed a private placement on June 17, 2026, increasing total shares outstanding. Yang did not buy or sell any Indaptus shares in connection with this change and reports sole voting and dispositive power over all his shares.
Yun Yao filed Amendment No. 2 to her Schedule 13D on Indaptus Therapeutics, Inc., updating her beneficial ownership in the company’s common stock. She beneficially owns 41,991,000 shares, representing 31.51% of the common stock, based on 133,242,324 shares outstanding as of June 24, 2026.
The amendment reports that her percentage stake fell by more than 1% solely because Indaptus increased its outstanding shares in a private placement that closed on June 17, 2026. Yao did not buy or sell any common shares in connection with this change.
Her position was originally acquired through a Securities Purchase Agreement dated March 19, 2026, using personal funds of $4,317,206.43 to purchase Series AA and Series AAA Preferred Stock, which later converted into common stock at the March 23, 2026 closing.
Indaptus Therapeutics, Inc. is registering for resale up to 18,864,000 shares of Common Stock by selling stockholders.
The prospectus states the Company will receive no proceeds from these resales and that the shares were issued principally upon conversion of preferred stock from the December 2025 financing and the March 2026 secondary transfer. The Company reports its last reported Nasdaq closing price was $3.775 per share as of June 22, 2026. The filing discloses that clinical development of Decoy20 has been paused: there are currently no participants in ongoing Decoy20 studies and the Company has substantially reduced Decoy20 development activities pending additional financing or strategic alternatives. The Company completed a June 17, 2026 private placement of 20,000,000 shares at $0.60 per share for gross proceeds of $12,000,000 and is required to file a resale registration covering those shares.
Indaptus Therapeutics entered into a Stock Purchase Agreement with certain non-U.S. accredited investors for a private placement of 20,000,000 shares of common stock at $0.60 per share. This generated aggregate gross proceeds of about $12,000,000 and represented less than 20% of shares outstanding before the deal.
The transaction was conducted offshore in reliance on Section 4(a)(2) and Regulation S, with no commissions paid. Investors received registration rights, requiring Indaptus to file a resale registration statement within 90 days of closing and to use best efforts to have it declared effective within 75 days after filing.
Indaptus Therapeutics, Inc. is soliciting proxies for its virtual 2026 Annual Meeting of Stockholders to be held July 28, 2026. The meeting asks holders to elect three Class II directors, ratify Haskell & White LLP as auditor, approve the 2026 Equity Incentive Plan (10% reserve) and to authorize private placements of up to $300 million at prices between $0.60 and $1.00 per share potentially exceeding 20% of outstanding stock.
The proxy materials state 113,242,324 shares outstanding as of June 12, 2026, that 11,324,232 shares are expected to be reserved under the 2026 Plan (10% of outstanding shares), and that any financing would be completed within 12 months following stockholder approval.
Indaptus Therapeutics, Inc. reported several leadership changes. Effective June 5, 2026, directors David E. Lazar and Avraham Ben-Tzvi resigned from all positions on the Board of Directors, including all committee roles. Effective June 1, 2026, Walt A. Linscott, Esq. resigned as Chief Operating Officer.
Linscott entered into a consulting agreement dated June 1, 2026 and will continue serving the company as a consultant in a strategic advisory role. The company stated that the resignations of Lazar, Ben-Tzvi, and Linscott were not the result of any disagreement with Indaptus on operations, policies, or practices.
Indaptus Therapeutics reported a Q1 2026 net loss of $2.54 million, improved from $4.53 million a year earlier, mainly because research and development spending fell to $0.49 million from $2.81 million as clinical activity was wound down. General and administrative expenses were stable at $1.67 million.
Cash and cash equivalents dropped to $1.50 million at March 31, 2026, after using $7.01 million in operating cash during the quarter. The company expects existing cash to fund operations only through the second quarter of 2026 and states there is substantial doubt about its ability to continue as a going concern.
All outstanding Series AA and Series AAA preferred shares issued in late 2025 converted into 111,000,000 common shares, bringing total shares outstanding to 113,242,324 at March 31, 2026. Indaptus has discontinued enrollment in its clinical studies and is evaluating strategic options for a post-investment transaction while keeping its immunotherapy platform as a potential asset.
Indaptus Therapeutics reported a first quarter 2026 net loss of about $2.5 million, improved from roughly $4.5 million a year earlier, as research and development spending declined sharply. R&D expenses fell to about $0.5 million from approximately $2.8 million, mainly from lower Phase 1 clinical costs and reduced payroll.
General and administrative expenses were about $1.7 million, slightly below the prior year. Cash and cash equivalents dropped to roughly $1.5 million as of March 31, 2026 from about $8.5 million at year-end 2025, with around $7.0 million used in operating activities in the quarter. The company states it will need to raise additional capital to support its business objectives and is evaluating financing alternatives and strategic options alongside a broader review of its development programs and Decoy platform.
Indaptus Therapeutics, Inc. received an ownership update from several large investors who amended their beneficial holdings and clarified their relationship. As of March 31, 2026, Yun Yao reports beneficial ownership of 41,991,000 shares of common stock, or 37.1% of the company. Sino Lion Ventures Limited and its controlling person, Chenhao Xu, each report 38,895,000 shares, representing 34.3% of the common stock. Junyi Dai and Ting Yang each report 11,250,000 shares, or 9.9%, while Lina Deng reports 5,550,000 shares, or 4.9%. All shares were issued upon conversion of Series AA and Series AAA Preferred Stock under a Securities Purchase Agreement that closed on March 23, 2026. The amendment states that the reporting persons have disbanded any group that may have existed under that agreement and will no longer act as a group, and it serves as an exit filing for Lina Deng, who fell below five percent ownership due to an increase in shares outstanding to 113,242,324.